Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotechnology VC (Venture Capital) Funds in Israel in January 2025

Last updated: Jan 2025 A list of 50 VC (Venture Capital) funds that invest in Biotechnology startups based in Israel. We rank investors based on the number of investments they made in Biotechnology companies from Israel. We update this investor list every month.

Top 50 Biotechnology VC (Venture Capital) Funds in Israel in January 2025

Investor	Biotechnology Israel investments
Pontifax	18
Trendlines Group	16
Israel Innovation Authority	9
OurCrowd	9
Docor International Management	7
OrbiMed	7
aMoon Fund	6
HBL Hadasit Bio Holdings	6
Arkin Holdings	6
ZORA Ventures	5
Sapir Venture Partners	4
Clal Biotechnology Industries	4
Accelmed	4
Millenium Food-Tech	4
iAngels	4
Takeda Ventures	4
Johnson & Johnson Robotics and Digital Solutions	4
Integra Holdings	4
New York Ventures	4
Cancer Focus Fund	3
Office of the Chief Scientist	3
Pitango VC	3
Welltech Ventures	3
Neo Ventures	3
Binder & Partners Ventures	3
FutuRx	3
EIT Food	3
Consensus Business Group	3
SciSparc	3
Triventures	3
fresh.fund	3
Ziegler Meditech Equity Partners	3
GlenRock Israel	2
Jerusalem Global Ventures	2
Ocean Azul Partners	2
ALIVE Israel HealthTech Fund	2
First Star Ventures	2
Arancia International	2
BRM Capital	2
Pfizer	2
DSM Venturing	2
VentureIsrael	2
Siddhi Capital	2
Flerie Invest	2
PeakBridge	2
Minrav	2
Fortissimo Capital	2
Amplifyher Ventures	2
NFX Bio	2
Agriline	2

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
Indapta Therapeutics — Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.

Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.

Investment focus

Biotechnology, Health Care, Medical Device
Seed, Funding Round, Series A
Israel, Singapore, United Kingdom

Portfolio highlights

AgriG8 — AgriG8 is an enterprise designed to align, collaborate, de-risk and grow value chains and ecosystems within the agricultural industry.
Peptobiotics — We make agriculture more productive, humane and sustainable by promoting growth and protecting against pathogens using a new new type of antibiotic alternative that does not cause resistance. Our recombinant peptides are synthetic biology products manufactured in a patent pending precision fermentation process. We are launching a range of products across livestock and aquaculture in Asia.
ViAqua Therapeutics — ViAqua is developing the first orally administered treatment in aquaculture to stop diseases from developing and to prevent viral epidemics.

The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.

Investment focus

Health Care, Medical Device, Biotechnology
Grant, Seed, Pre-Seed
Israel, United States, Mali

Portfolio highlights

Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
i-EcoGuard — I-Ecoguard is pioneering sustainable agriculture with cutting-edge nanoparticle technology. Our objective is to improve greenhouse efficiency, plant health, and crop quality.
Eretz Angels — Eretz Angels supports technology startups in Israel's outskirts at the start of their journey.

Access exclusive venture capital angel investment deals in pre-vetted startup companies. Create your free OurCrowd investor account today!

Investment focus

Software, Artificial Intelligence, Machine Learning
Series B, Series A, Seed
Israel, United States, New Zealand

Portfolio highlights

Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
Kando — Kando is an end-to-end solution that creates continuous awareness of events in the collection system. Kando enables utilities to remotely and continuously improve their operations by providing the following features:• Realtime wastewater quality data across the collection system • Pinpoint sources of pollution • Early warnings of damaging WWTPinfluent quality • Machine learning that evolves with your network • Autonomous sampling units • User fee calculator • Customized pollution alerts • A user-friendly, online interface • Detection of COVID-19 infection rates (New)The combination of these actionable insights results in:• Reduced CAPEX/OPEX • Greater WW reuse capabilities • Improved public health • Cleaner environmentsKando has been deployed in Los Angeles, Milan, Brisbane, and many other cities. To gain a greater understanding of how our system can help your organization, visit our homepage at www.kando.eco.
Blue Tree Technologies Ltd. — Blue Tree’s mission is to develop a sugar reduction platform for industrial applications in the drinks industry.

Docor International B.V. is a fully-owned subsidiary of Crecor B.V. Both Docor and Crecor were formed as wholly-owned subsidiaries of the Van Leer Group Foundation to promote and participate in commercial activities in Israel.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Funding Round, Series C, Series A
Israel, United States

Portfolio highlights

Check-Cap — The first and only patient-friendly preparation-free test to detect polyps before they may transform into cancer
Ocon Healthcare — OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.
Raziel Health — Raziel Health’s mission is to bring world-class, disruptively less expensive healthcare to everyone, in the comfort of their home. Its unique, integrated system combines easy-to-use technologies that support positive patient experience, enable timely clinical intervention, and meet individual patient goals while using data analytics to supportwellness and disease management.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Aviceda Therapeutics — Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively.

aMoon is a leading healthtech & life sciences venture capital firm.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Funding Round
United States, Israel, Switzerland

Portfolio highlights

Lyfegen — Lyfegen is the first of its kind, a company making value-based healthcare contracting for high-cost therapies a reality for all healthcare stakeholders.
PrognomiQ — PrognomiQ is invested in transforming the detection and early treatment of cancer and other complex diseases. Learn more about our test products and careers.
MetaSight Diagnostics — MetaSight Diagnostics, a health technology company, is on a mission to develop affordable and precise liquid biopsy diagnostics for the early detection of a wide range of chronic and acute diseases by leveraging proprietary mass spectrometry technologies (metabolomics, lipidomics, and proteomics).

Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Series A, Series B
Israel

Portfolio highlights

ProtAb — ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
Enlivex Therapeutics — Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.

Explore Arkin Capital: A leading multi-asset manager driving strategic investments across health, technology, equity, real estate and more

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
Israel, United States, Switzerland

Portfolio highlights

Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
Honeycomb — Honeycomb (fka Agilius) is the only place where you can buy a condo/apartment building master policy online in less than 3 minutes at a fraction of the cost! Instant, free, no hassle quotes, online everything and up to 40% savings. With all that we're bringing simplicity and transparency to the real estate insurance space for condoassociations (HOAs), building owners, property managers, and developers everywhere. This is what we do. This is all we do.
Nocion Therapeutics — Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation.

Impact investing in Israeli technology. ZORA is an impact investing fund investing in early-stage Israeli companies solving global challenges in health, education, economic inclusion and the environment.

Investment focus

Health Care, Biotechnology, Internet
Seed, Series A, Convertible Note
Israel, United States, United Kingdom

Portfolio highlights

BiotaX — Microbiome Genomic Analysis Cloud Platform | Biotax.co
Newmoo — Newmoo makes plant-based cheeses and dairy alternatives.
Forsea Foods — Forsea Foods develops cell-cultured seafood through the use of patented organoid technology which allows them to bypass the scaffolding stage of cultivated meat production.

Early Stage VC

Investment focus

Software, Biotechnology, Machine Learning
Seed, Pre-Seed, Series A
Israel, United States, United Kingdom

Portfolio highlights

Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
DeepCure — DeepCure is a Boston-based therapeutics company that harnesses advanced AI, physics-based tools and automation to discover novel small molecules for challenging targets. DeepCure currently has a lead asset in IND-enabling studies and other programs focused on drugging intractable targets that have t

Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI)

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Israel, United States

Portfolio highlights

Sight Diagnostics — Combining AI and breakthrough hardware to bring lab-quality CBC results to the doctor's office.
Cadent Therapeutics — Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts.
Elicio Therapeutics — Elicio ground-breaking Amphiphile technology is engineering potent vaccines and immunotherapies to defeat an array of aggressive cancers.

Accelmed is a venture capital firm that funds private and public medical device companies with significant market potential and proven clinical data.Concentrating on medical device companies that have already reached the revenue stage enables the firm to assist companies in benefiting from its managerial capabilities and financial resources.Together with the management teams of their portfolio companies, the Accelmed can steer the way from the clinical-stage to a profitable business with a clear commercial plan, thereby accelerating the path to a successful exit.In 2009, Mori Arkin and Uri Geiger, the co-founders of Accelmed, established the firm in Herzliya, Tel Aviv.

Investment focus

Health Care, Medical Device, Medical
Funding Round, Series A, Series D
Israel, United States

Portfolio highlights

Revamp Medical — Revamp medical was founded in 2016 with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. Targeting a market of >1M annual admissions in the US with a direct cost of $65B, Revamp is set to deliver an easily adoptable solution using its patented temporary catheter, Doraya™.Revamp has a seasoned team ofprofessionals with a proven track record in leading multiple med-tech startups.
Minerva Surgical — Minerva Surgical develops minimally invasive devices to treat the root causes of Abnormal Uterine Bleeding.
Click Therapeutics — Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive datascience platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

Millennium Food-Tech is an R&D partnership traded on the Tel Aviv Stock Exchange that specializes in investment in and betterment of companies in food-tech sectors,. Millennium seeks to invest in companies that specialize in identifying and developing innovative, and transformative ideas in the food, drinks, and nutrition industry. Millenniumhas experienced management, proven solutions, and a supportive network to develop ideas and start-ups from early-stage to maturity to exit.

Investment focus

Food and Beverage, Manufacturing, Agriculture
Seed, Series A, Convertible Note
Israel

Portfolio highlights

ansā — Objectively Awesome Coffee
Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
Supersmart — Supersmart is the world's leading loss-prevention solution for self-scan transactions. Supersmart uses its proprietary machine-learning, AI algorithm to validate all self-scanning transactions in physical stores. Our solution enables retailers to confidently provide self-scanning options to their customers, enhancing customer experiencewithout sacrificing potential loss.The Israel-based company was founded in 2014 by Yair Cleper and Amir Ayalon.

Invest in groundbreaking startups with iAngels. Discovercutting-edge technology and join a community of forward-thinking investors shapingthe future of entrepreneurship.

Investment focus

Artificial Intelligence, Software, Financial Services
Seed, Series A, Funding Round
United States, Israel, United Kingdom

Portfolio highlights

Mawari — Our mission is to unlock new perspectives with real-time immersive technology powered by a decentralized network of global resources
Lava Network — Lava Network aims to be a marketplace for blockchain data.
Alliance Games — Next level Web3 Gaming Infrastructure, Now Fully Decentralized

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Healthcare innovation wherever it originates.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Israel, United Kingdom

Portfolio highlights

Moon Surgical — Create the OR of the future, one that is sustainable, efficient, and digitalized.
Artera — Discover the power of Personalized Precision Medicine & AI Cancer Therapy with Artera. Transforming cancer therapy through innovation.
ONL Therapeutics — ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with

Investment focus

Biotechnology, Pharmaceutical, Life Science
Seed, Series B, Series F
Israel

Portfolio highlights

BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
Splisense — Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried.
Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria

New York Ventures is dedicated to encouraging innovation and fueling economic growth in communities across the State. This venture capital investment arm of Empire State Development is one of New York State's business resources and innovation investments, including the Governor's START-UP NY program, Innovation Hot Spots, the RegionalEconomic Development Councils, the Centers of Advanced Technology and Centers of Excellence networks, and the SUNY 2020 Initiative.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United States, Canada, Israel

Portfolio highlights

ZeroMark — ZeroMark is a defense product company building technology to ensure safety and precision when using kinetic and non lethal weapons.
Cell BioEngines — Cell BioEngines, Inc., is a clinical-stage biotech company focused on curing cancer by developing ”off-the-shelf” allogenic cell therapies. The company leverages its proprietary Stem-SPACE platform technology to produce clinical grade cells at scale.
Dimensional Energy — We transform carbon dioxide into sustainable aviation fuel.

Cancer Focus Fund is an investment firm that is dedicated to providing financial services to its clients. The company was founded by Ross Barrett.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Seed, Series A
Israel, United States, Germany

Portfolio highlights

Eisbach Bio — Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors. It is founded in 2019 and is based in Martinsried, Bavaria.
March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
Starget Pharma — Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues.

The Office of the Chief Scientist [OCS] in the Ministry of Economy is charged with execution of government policy for support of industrial R&D. The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel’sscientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high tech entrepreneurship.

Investment focus

Health Care, Biotechnology, Hardware
Seed
Israel

Portfolio highlights

LapSpace — LapSpace Medical was founded in 2011. It operates within the framework of the Misgav Venture Accelerator, part of The Trendines Group. The LapSpace team combines strong business and medical experience and knowledge.
Digma Medical — Digma Medical | DiaGone - safe, one-time, 30 minute, minimaly-invasive, GI procedure for Restoring Glycemic Control for T2DM & NASH patients | No Implant
Immunovative Therapies — Immunovative Therapies is a biopharmaceutical company with financial support of the Israel Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world renown Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstandingincubator project of 2006, awarded by the Office of the Chief Scientist. They specialize in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for the treatment of cancer and infectious disease.

Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.

Investment focus

Software, Health Care, Information Technology
Series A, Series B, Series C
Israel, United States, China

Portfolio highlights

Homethrive — Homethrive is dedicated to helping families care for their loved ones who are aging or have special needs. Discover how our caregiving solution, Dari, can help you!
Guardoc Health — Streamlining clinical compliance with AI-driven accuracy in charting to meet regulations, enhance patient care, and optimize revenue management.
Quantum Source — Quantum Source is on a clear path to the most powerful, cost-effective, practical photonic quantum computer. Learn more.

Welltech Ventures is Israel’s leading fund focused exclusively on investing in the health and wellness space. We seek to partner with entrepreneurs who epitomize the Startup Nation’s ethos and are building paradigm-shattering companies that are making an impact in the wellness space. As thought leaders we work with global investors focused onaccessing and investing in the Israeli tech ecosystem’s most promising entrepreneurs.

Investment focus

mHealth, Health Care, Biotechnology
Seed, Funding Round, Pre-Seed
Israel, United States

Portfolio highlights

Antidote Health — AntidoteHealth.ai offers primary care on its telehealth app on a 24/7 basis, including prescriptions & more. Book your appointment today!
Behavidence — Behavidence is a mental health application that generates a daily mental health score. It compares your digital behavior to other people with anxiety, depression and ADHD.
Quris — Quris Technologies is an artificial intelligence (AI) innovator disrupting the pharmaceutical arena.

Neo Ventures is the first open-ended early stage investor, based in Eastern Europe. The founders have backed more than 30 startups and exited 10 successfully. We invest in game-changing businesses, without geographic limitations. We partner with exceptional founder teams to challenge incumbents in markets ripe for change or to create entirely newmarkets. Neo Ventures funds and then supports the founders in business planning, scaling operations, follow-on investments, making the best of each opportunity and dealing with hard situations. Our investment focus is on data analytics, computer vision and remote sensing addressing disruptive opportunities across the high-growth SpaceTech, BioTech and Security verticals.

Investment focus

Software, Artificial Intelligence, Aerospace
Seed, Funding Round, Series A
Israel, United Kingdom, Estonia

Portfolio highlights

EnduroSat — At EnduroSat, we engineer, build and operate exceptional satellites. Our Mission is to make space universally accessible
Cyberwrite — TRUSTED BY INDUSTRY LEADERS One platform to accelerate value across the cyber insurance lifecycle THE LATEST FROM CYBERWRITE
GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.

Binder & Partners Ventures is the investments' capital arm of Binder & Partners multi-family office. The ambition of BPV is to connect our investors with the most promising startup companies.

Investment focus

Software, Information Technology, Health Care
Seed, Pre-Seed, Series A
Israel, France, United States

Portfolio highlights

Rookout — Speed up the debugging process and accelerate your team's velocity with Rookout's live, remote debugging platform. Debug anything, anywhere. Effortlessly.
Lumen — Lumen is a device and app that measures your metabolism in a single breath and provides daily personalized nutrition based on your metabolic data. Through the device and app, you can achieve your fitness goals whether they be weight loss, performance optimization, or simply improving your metabolic health.As a company, we are a team ofscientists, researchers, engineers, and designers, aimed at improving the way people understand their metabolism. We believe that a healthy metabolism is a key to better health and that everyone can attain it with a little help from Lumen.At Lumen, we are all about teamwork, friendship, and family. Curious about joining? We are always looking for creative people who share our passion for health and fitness to join our team.
Blink Technologies — Blink creates the ultimate interaction between your eyes & the world around you with our eye tracking software & eye tracking technology.

FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.

Investment focus

Biotechnology, Life Science, Biopharma
Seed, Funding Round
Israel

Portfolio highlights

Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
Bsense Bio Therapeutics — Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety.

EIT Food is a European Knowledge and Innovation Community (KIC), which was set up to transform our food ecosystem. By connecting consumers with businesses, start-ups, researchers and students from around Europe, EIT Food supports innovative and economically sustainable initiatives which improve our health, our access to quality food, and our environment

Investment focus

Food and Beverage, Biotechnology, Food Processing
Grant, Funding Round, Seed
United Kingdom, Israel, Germany

Portfolio highlights

Gavan — Transforming the way proteins are delivered. Our technology extracts high purity proteins from source while maintaining their physical structure unharmed and preserving their high functionality.
Orbisk — One-third of all food produced (worldwide) is wasted. Orbisk helps professional kitchens to get a grip on their food waste.
New Wave Biotech — New Wave Biotech's AI Downstream Process Optimization Software empowering SynBio innovators to get to market quicker, better and at lower cost. By simulating bioprocesses, techno economic analysis and auto optimisation, we help precision fermented alternative protein and other industrial biotechnology products improve yield and scale production.

Acting as advisor to companies within the Tchenguiz Family Trust, Consensus Business Group has amassed a portfolio of over 300,000 residential freeholds worth over £4 billion and a commercial portfolio worth over £2 billion.Consensus Business Group has vast experience and a proven track record of acquiring stock directly from nationalhousebuilders and developers over 20 years.As a result of their strategic investment, Consensus Business Group is believed to be the largest owner and asset manager of residential freehold interests in the UK, representing in excess of 1% of the housing stock in England and 1.2% in Greater London.Their decisions are not subject to procrastinated board approval or credit committees and as a result they are able to perform quickly and consistently. They are not dependent on debt finance and they have immediate cash availability.Consensus Business Group prides itself on having the market knowledge and expertise to stand out from its competitors, and it is their diligent and efficient acquisition practices that ensure swift transactions.

Investment focus

Health Care, Medical Device, Biotechnology
Funding Round, Seed, Series B
Israel, United States, United Kingdom

Portfolio highlights

BioProtect — Visualize the Space Optimize prostate radiation treatment with confidence CT MRI CBCT A Visibly Different Solution Reproducible & Adjustable Create a un ...
Exero Medical — Exero Medical is a medical device manufacturing company. It develops a biodegradable wireless sensor for early detection of anastomotic leaks following GI Surgery. Its system is designed to prevent complications by warning physicians of a potential leak, enabling early intervention.The company was founded in 2018 and is headquartered in OrYehuda, Israel.
RepAir — RepAir develops a Direct Air Capture system based on a proprietary electrochemical cell technology that can capture CO2 from the air in gigaton scale. Powered solely by renewable energy, our system can be deployed at the site of carbon storage or utilizations, saving arable land and avoiding CO2 transport.

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based ontetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.

Investment focus

Pharmaceutical, Cannabis, Biopharma
Funding Round, Corporate Round
Israel

Portfolio highlights

LaraPharm — LaraPharm Ltd. is a group of people joined together by the belief that active components found in the Cannabis plant can provide a real answer to hundreds of types of disease currently not addressed at all, or poorly addressed.
MitoCareX Bio — MitoCareX Bio is a biotechnology company that focuses on the discovery and development of drugs for cancers & other life-threatening diseases.

Triventures is a global, early stage fund that invests in exceptional entrepreneurs. We partner with disruptive ventures with innovative breakthroughs in healthcare and beyond. Our vision is to create a better, healthier future through data driven solutions and cross industry convergence.

Investment focus

Health Care, Medical Device, Medical
Funding Round, Series A, Series B
United States, Israel, Ireland

Portfolio highlights

Grin — Grin is a comprehensive digital orthodontic platform providing teeth straightening for all types of patients with a real local orthodontist. The platform also connects patients with a real orthodontist from the convenience of their smart device. They deliver responsible care from orthodontic specialists in an easily accessible and cost-effectiveway, Grin provides patients quality care that results in an exceptional smile together with all of the modernized convenience that they expect.Grin technology, aligned with a network of local trusted orthodontists, ensures that every patient gets the right care. The platform Grin App and Grin Scope is a patent-pending technology that offers remote monitoring for a variety of orthodontic needs. The Grin experience includes high-quality self-scans with the latest teeth straightening solutions. Practitioners and patients can now use these telemedicine tools to achieve a new, more convenient treatment journey.It was founded by Dr. Adam Schulhof, Pamela Oren-Artzi, and Alon Lipnik in 2019 and is based in New York and Austin.
Cala Health — Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
TailorMed — Moving Mountains for Patients

fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.

Investment focus

Health Care, FinTech, Education
Seed, Pre-Seed, Series A
Israel, United States, Norway

Portfolio highlights

enso — enso offers AI-powered bot bundles to automate your marketing strategy. Perfect for small business owners, our bots handle social media, SEO, lead generation & much more. Start with a 7 days free trial or talk with one of our marketing experts today.
Carbon Blue — Carbon Blue is developing an 'ocean-capture' scalable method for removing CO2 from the atmosphere. The company was founded by Iddo Tsur and Dan Deviri.
Guardoc Health — Streamlining clinical compliance with AI-driven accuracy in charting to meet regulations, enhance patient care, and optimize revenue management.

Ziegler is a privately held investment bank, capital markets and proprietary investments firm.

Investment focus

Health Care, Biotechnology, Mobile
Series C, Series E, Series F
United States, Israel

Portfolio highlights

Aposense — Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel.
MAKO Surgical — MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specificosteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal.MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.
MobileAccess Networks — Corning Everon Network Solutions offer in-building cellular solutions to meet a broad array of design scenarios and mitigate RF propagation challenges.

A Private Equity Investment Company Founded by Leon Recanati in 2003, GlenRock leverages a unique combination of private equity, multidisciplinary in-house expertise, unmatched access to quality dealflow, and a focused but flexible investment strategy to achieve maximum returns.

Investment focus

Software, Cyber Security, Transportation
Seed, Series B, Series A
Israel, United States

Portfolio highlights

Cylus — Cylus, the global leader in rail cybersecurity, helps rail, freight and metro companies avoid service disruption and safety incidents by detecting cyber-attacks in their signaling and control networks, wayside and onboard, before harm happens.
Treetoscope — The first and only commercial device that senses the internal water flow of a plant and directly measures its water consumption and real-time irrigation needs. without extrapolations based on indirect sensing technologies.Treetoscope offers a SaaS irrigation management platform, based on direct plant sensing technology. We tackle one of the mostcrucial challenges farmers face today: water scarcity and irrigation optimization. Our groundbreaking ag-tech enables the unprecedented measurement of real-time actual water use of trees (based on our patented single probe Sap Flow sensor). Through the Treetoscope solution, growers gain great value as a result of the affordability, scalability, and ease of deployment of our technology.
Quris — Quris Technologies is an artificial intelligence (AI) innovator disrupting the pharmaceutical arena.

Since the firm was founded in 1994, Jerusalem Global's goal has been to support private Israeli technology initiatives and to generate superior returns to investors. Over the last two decades, the partners of Jerusalem Global Ventures have developed strong ties with the top Israeli entrepreneurs and visionaries enabling JGV to invest in thebest of Israel's entrepreneurs and help their portfolio companies build winning management teams.

Investment focus

Software, Information Technology, Biotechnology
Series A, Series B, Series C
United States, Israel, Canada

Portfolio highlights

Moovit — Utilizing the power of MaaS, we're helping cities, transit agencies and corporations simplify urban mobility, making it more efficient, accessible and sustainable.
Quiet Therapeutics — Quiet Therapeutics is an emerging biotech company founded in 2010 developing a proprietary nanoparticle-based delivery system (gagomers) focused on oncology and inflammation.Based on the targeting capability of our innovative technology, the company is well positioned to expand the drug target repertoire in cancer and inflammation. The Gagomerdelivery approach enables us to target cell components that are not manageable by other therapeutic agents like small molecules or antibodies.
SolarEdge Technologiesa — Turn your businesses and homes into a sustainable energy hub with a SolarEdge inverter solution and the SolarEdge energy manager platform.

We are an early stage venture capital fund passionate about helping entrepreneurs bring innovative solutions to market.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Funding Round
United States, Israel, Australia

Portfolio highlights

qbiq — qbiq develops cutting-edge Artificial Intelligence, Generative Design, and Optimization Technologies to real-estate planning.With a click of a button, hundreds of cloud processors, loaded with thousands of years of architectural experience, process your planning request, analyze different layout alternatives, and optimize the results. In justseconds, we provide you with the best construction alternatives considering utilization, costs, build time, efficiency, and more.
Fortify — 3DFortify is an advanced manufacturing startup that aims to disrupt additive manufacturing, ushering in a new generation of custom, high performance products. We have developed a patented process that combines 3D printing and magnetics to create aligned reinforced carbon fiber composites.
Intracare Health Services — Intracare Health Services offers advanced infusion therapy services through our outpatient infusion clinics and infusion pharmacy. We are state and federally licensed, insured, and nationally accredited.

ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.

Investment focus

Health Care, Medical, Biotechnology
Series A, Funding Round, Series B
Israel, United States

Portfolio highlights

Append Medical — Append Medical develops a next-generation transcatheter Left Atrial Appendage (LAA) closure system.The Append Medical solution is in the pre-clinical in-vivo trial phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growingsegment of the medical device market, with potential sales of $500M in 2019. Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center.
Magenta Medical — Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
Gina Life — At Nevia bio, we are focused on women's health. Our mission is to use innovative technologies to provide early detection of diseases through vaginal secretions analysis, enabled by Nevia's Machine Learning Platform.

Investing with conviction in visionary, technical founders inventing the future.

Investment focus

Software, Artificial Intelligence, Biotechnology
Seed, Pre-Seed, Series A
United States, Canada, Israel

Portfolio highlights

Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
Bot Auto — Bot Auto develops and operates autonomous trucks for middle-mile freight.
Phaseshift Technologies — Phaseshift Technologies is developing a Computational Materials Engineering (CME) platform to help accelerate the Research and Development of High-Performance Alloys. The CME platform is driven by Quantum Chemistry calculations and aided by Machine Learning based predictive algorithms.

Arancia International Inc is a part of Arancia Group in Mexico. We are long term investors in food, nutrition and biotechnology companies.

Investment focus

Health Care, Biotechnology, Life Science
Series A, Series B, Funding Round
Israel, United States, Malaysia

Portfolio highlights

NextFerm — NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value.At Nextferm, they aim to use their capabilities to lead this new and exciting world of better nutrition.
iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.

BRM Capital is a dynamic venture capital fund investing in early stage, Israel-related software, internet infrastructure, and communication companies. Their investment focus is on the Internet, mobile and mobile applications, digital media, online services, enterprise software, and medical device sectors and they also offer flexible, streamlinedinvestment decision making.BRM headquartered in Tel Aviv, Israel enjoys a worldwide network of industry, strategic and financial experts.

Investment focus

Software, Information Technology, Internet
Series B, Series A, Funding Round
United States, Israel

Portfolio highlights

V-Wave — V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave hasdeveloped a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.
ShopperAI — ShopperAI is a company that provides AI-powered shopper research and analytics tools to understand customer behavior and grow the business.
Exceed Talent Capital — Exceed is an innovative platform to invest, earn, engage, influence, and celebrate Talent.

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Post-IPO Equity, Series A, Corporate Round
United States, Israel, France

Portfolio highlights

CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.

Investment focus

Biotechnology, Health Care, Manufacturing
Series A, Funding Round, Series B
United States, Canada, Israel

Portfolio highlights

Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
NutriLeads — NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.

Israeli Early Stage Deep Tech Fund

Investment focus

Information Technology, Software, Cyber Security
Seed, Pre-Seed, Series A
Israel

Portfolio highlights

Wib Security — Wib is the only way to secure your APIs from development to production, with the most comprehensive full-lifecycle API Security Platform.
Cydome — Cydome offers comprehensive maritime cybersecurity solutions for protecting IT and operational assets at sea, ensuring readiness for regulatory inspections.
Cyngular Security — Cyngular Security - Cloud Autonomous Hunting, Investigation and Response Platform Helps organizations proactively prepare for and respond to cyber security incidents, ensuring maximum protection and minimum downtime.

Siddhi Capital is the growth equity partner for convention-crushing food and beverage companies.

Investment focus

Food and Beverage, Biotechnology, Food Processing
Seed, Series A, Series B
United States, Israel, Canada

Portfolio highlights

Ingrediome — We are developing an animal-free protein emulsifier that is radically superior to anything in the market today.
Liberation Labs — Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech.
Plantible Foods — We are developing the best tasting and most functional, sustainable plant-based protein by using lemna, also known as duckweed

Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally.

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Sweden, Israel, Iceland

Portfolio highlights

AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
XNK Therapeutics — XNK Therapeutics, founded in 2012, is one of the pioneering companies within the landscape of cell therapy.
Vitara Biomedical — Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.

PeakBridge is a global impact VC that funds and connects the people, technology and processes that will shape the future of food.

Investment focus

Food and Beverage, Food Processing, Health Care
Series A, Seed, Funding Round
Israel, United States, United Kingdom

Portfolio highlights

BE WTR — The first premium sustainable water brand aiming to promote a more ecological water consumption and to contribute to a better hydration thanks to its technological and design water systems. | Discover more about us.
Mondra — AI-driven environmental insights platform that supports food system players to accelerate Scope 3 progress, reduce the cost of Net Zero, and drive competitive advantage.
Orbisk — One-third of all food produced (worldwide) is wasted. Orbisk helps professional kitchens to get a grip on their food waste.

Minrav provides engineering and construction services.

Investment focus

Health Care, Hospital, Wellness
Series A, Funding Round
Israel, Malaysia

Portfolio highlights

iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
Qualitas Health — Qualitas Health Group aims to serve patients through a network of 500 clinics by 2022 with quality healthcare services across the Asia Pacific.

Fortissimo Capital is a leading private equity fund in Israel investing primarily in technology and industrial companies. We take a unique, hands-on approach to ...

Investment focus

Manufacturing, Software, Information Technology
Funding Round, Series B, Series C
Israel, United States, Italy

Portfolio highlights

Velox — Velox develops and manufactures industrial-grade direct-to shape digital decoration solutions for the rigid container industry. Their proprietary DTS-Inkjet technology, based on uniquely formulated inks and dedicated deposition architecture, introduces an entirely new approach to digital printing that is poised to disrupt the packaging decorationmarket.Their debut product is the Velox IDS 250 – the first industrial-grade digital decorator for mass production of cylindrical containers available on the market. It delivers superior decoration quality and capabilities that outstrip analog printing solutions, while allowing a more efficient and flexible production process and a low total cost of ownership (TCO).Velox is powered by an expert team with uniquely extensive and wide-ranging experience in digital printing. It is led by veteran executives with proven success in driving company growth.
Equinom — Equinom is a fully integrated food-tech company, combining agricultural know-how, culinary expertise and deep technology to develop delicious, nutritious, affordable and sustainable non-GMO plant-based ingredients – from the ground up.Sustainable, plant-based proteins are key to feeding Earth’s 10B people by 2050 The plant-based food market grew27% in 2020 and is projected to reach $162B by 2030.The industry is unable to supply the full demand for food vs. feed For decades, crops have been farmed primarily for animal feed – not for human consumption. To be palatable in human food, these crops require extensive and expensive processing. . With limited processing facilities equipped for this use, the industry is on track to supply only 50% of projected demand for plant-based foods.What is Equinom doing about it? Equinom is using science and technology to develop superior ingredients naturally, at the source – in a fraction of the time typically required to breed new crops. Equinom crops are bred naturally, without genetic editing or modification, and are optimized to make meat and dairy analogues more delicious, nutritious, cost-effective and sustainable. Ingredients designed by deep tech to bring out nature’s best The company’s proprietary Manna™ technology platform uses AI to speed the development of superior, high-yield, non-GMO ingredients as nature intended – featuring the quality traits that satisfy consumer expectations. The technology also ensures biodiversity and climate resilience that are critical to ensure food security in light of climate change. What makes Equinom a compelling foodtech investment and collaborator? Working with great partners including Meatless Farm, Roquette with GoodMills Group., Equinom is recognized as a trusted developer and supplier of unrivaled ingredients. Prestigious strategic investors such as BASF and Roquette have helped position Equinom as one of the breakout Round C companies to fuel the worldwide surge in plant-based eating.
Beewise — Beewise offers robotic beehives that operate with minimal human intervention, by utilizing AI-powered precision robotics. The company's solution automates all beekeeping activities in order to increase yield, reduce colony loss, and eliminate the use of chemical pesticides. We are the first comprehensive solution that keeps bees alive, inspite of all the stressors and challenges they face, allowing them to thrive, pollinate, and produce honey.

Venture capital fund investing in female founders and women leaders

Investment focus

Health Care, E-Commerce, Fashion
Seed, Series A, Pre-Seed
United States, Israel

Portfolio highlights

AVEC — Premium, low sugar mixers made with real juice, real fruit, and all natural ingredients. Low in calorie, high in flavor. Don't compromise what you mix with your spirit.
Droplette — Finally, a tool to deeply infuse skin with your favorite actives. Let that sink in. Droplette makes ingredients tiny and fast to get under your skin.
Expressable — Expressable is an online speech therapy practice for everyone with a communication disorder. It has pioneered a parent-focused care model that uses technology and education to integrate speech therapy techniques into children's daily lives, improving outcomes and experiences.The company was founded in 2019 and is headquartered in Austin,Texas.

NFX Bio is a fund initiative that seeks to invest in scientist-founders at the seed stage with a technology platform approach.Led by Omri Amirav Drory, a venture partner with NFX, who founded Genome Compiler, it helps scientists learn to be founders and guides biology companies with information technology to be a critical distinction with massiveimplications.

Investment focus

Biotechnology, Therapeutics, Medical
Seed
Israel, United States

Portfolio highlights

resistanceBio — Identify the primary drivers of clinical trial success with ENCER cancer models.
Radar Therapeutics — Precision-targeted, smart therapies to conquer the world's most intractable diseases.
Eleven Therapeutics — Harnessing the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.

Agriline is the investment vehicle owned by a trust of which Trendlines' controlling shareholder Vincent Tchenguiz.

Investment focus

Health Care, Medical Device, Medical
Seed, Funding Round, Series A
Israel

Portfolio highlights

Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
Vessi Medical — Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).
SetBone Medical — SetBone Medical develops a new bone cement for the treatment of VCF and primarily caused by osteoporosis.

Investors by industry